Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Analysts: "Hold" — Zimmer Biomet has a consensus Hold rating from 23 analysts (3 sell, 12 hold, 7 buy, 1 strong buy) with an average 12‑month price target of about $105.95.
• Earnings & guidance — ZBH beat Q4 estimates (EPS $2.42 vs. $2.38; revenue $2.24B vs. $2.22B, +10.9% YoY) and set FY2026 guidance of $8.30–$8.45 EPS, essentially in line with the street (~$8.39).
• Institutional ownership surge — Hedge funds/institutions own ~88.9% of the stock, with large recent buys (M&T Bank added ~3.55M shares) and major positions held by firms like Dodge & Cox (23.2M shares, ≈$2.29B).

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) has received an average recommendation of "Hold" from the twenty-three brokerages that are presently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $105.9524.

A number of equities analysts have recently issued reports on the stock. Sanford C. Bernstein raised their target price on shares of Zimmer Biomet from $97.00 to $99.00 and gave the stock a "market perform" rating in a research report on Friday, January 9th. William Blair assumed coverage on shares of Zimmer Biomet in a research report on Friday, February 20th. They set a "market perform" rating on the stock. TD Cowen upgraded shares of Zimmer Biomet from a "hold" rating to a "buy" rating in a research report on Monday, January 26th. Citigroup restated a "buy" rating on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Finally, Leerink Partners initiated coverage on shares of Zimmer Biomet in a research report on Monday, April 13th. They issued a "hold" rating and a $101.00 price objective on the stock.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares in the company, valued at $967,803.84. This trade represents a 20.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.28% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zimmer Biomet

A number of hedge funds and other institutional investors have recently bought and sold shares of ZBH. M&T Bank Corp grew its position in Zimmer Biomet by 15,705.6% in the 4th quarter. M&T Bank Corp now owns 3,571,595 shares of the medical equipment provider's stock valued at $321,158,000 after buying an additional 3,548,998 shares during the last quarter. Norges Bank purchased a new position in Zimmer Biomet in the 4th quarter valued at $221,234,000. Franklin Resources Inc. grew its position in Zimmer Biomet by 43.2% in the 4th quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider's stock valued at $601,204,000 after buying an additional 2,017,857 shares during the last quarter. Auto Owners Insurance Co grew its position in Zimmer Biomet by 8,892.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,009,712 shares of the medical equipment provider's stock valued at $180,713,000 after buying an additional 1,987,362 shares during the last quarter. Finally, Dodge & Cox grew its position in Zimmer Biomet by 5.1% in the 3rd quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider's stock valued at $2,286,793,000 after buying an additional 1,118,710 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $91.27 on Friday. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. The firm has a market cap of $17.67 billion, a PE ratio of 25.78, a price-to-earnings-growth ratio of 1.89 and a beta of 0.61. The company's 50 day simple moving average is $93.59 and its 200-day simple moving average is $93.09. Zimmer Biomet has a 12-month low of $84.59 and a 12-month high of $108.29.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.38 by $0.04. The business had revenue of $2.24 billion for the quarter, compared to analyst estimates of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company's revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period last year, the firm posted $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, equities analysts predict that Zimmer Biomet will post 8.39 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is 27.12%.

About Zimmer Biomet

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.